Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Daniele Roberto Giacobbe, Jason A. Roberts, Mohd H. Abdul-Aziz, Etienne de Montmollin, Jean-François Timsit & Matteo Bassetti. (2022) Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective. Expert Review of Anti-infective Therapy 20:7, pages 963-979.
Read now
Read now
Cristina Sarda, Farhan Fazal & Jordi Rello. (2019) Management of ventilator-associated pneumonia (VAP) caused by resistant gram-negative bacteria: which is the best strategy to treat?. Expert Review of Respiratory Medicine 13:8, pages 787-798.
Read now
Read now
Kirsten Busey, Jason Ferreira, Petra Aldridge, Donald Johnson, Nilmarie Guzman & Christopher A. Jankowski. (2016) Treatment efficacy of Ampicillin/Sulbactam in comparison to alternative beta-lactams for severe Acinetobacter baumannii infections. Infectious Diseases 48:10, pages 775-777.
Read now
Read now
Huang-Shen Lin, Ming-Hsun Lee, Chun-Wen Cheng, Po-Chang Hsu, Hsieh-Shong Leu, Ching-Tai Huang & Jung-Jr Ye. (2015) Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus–Acinetobacter baumannii complex. Infectious Diseases 47:6, pages 370-378.
Read now
Read now
José Garnacho-Montero, Rosario Amaya-Villar, Carmen Ferrándiz-Millón, Ana Díaz-Martín, José María López-Sánchez & Antonio Gutiérrez-Pizarraya. (2015) Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia. Expert Review of Anti-infective Therapy 13:6, pages 769-777.
Read now
Read now
Jordi Vila & Jerónimo Pachón. (2012) Therapeutic options for Acinetobacter baumannii infections: an update. Expert Opinion on Pharmacotherapy 13:16, pages 2319-2336.
Read now
Read now
Argyris Michalopoulos & Matthew E Falagas. (2010) Treatment of Acinetobacter infections. Expert Opinion on Pharmacotherapy 11:5, pages 779-788.
Read now
Read now
Alex P Betrosian & Emmanuel E Douzinas. (2009) Ampicillin-sulbactam: an update on the use of parenteral and oral forms in bacterial infections. Expert Opinion on Drug Metabolism & Toxicology 5:9, pages 1099-1112.
Read now
Read now
Matteo Bassetti, Elda Righi, Silvano Esposito, Nicola Petrosillo & Laura Nicolini. (2008) Drug Treatment for Multidrug-Resistant Acinetobacter Baumannii Infections. Future Microbiology 3:6, pages 649-660.
Read now
Read now
Jordi Vila & Jerónimo Pachón. (2008) Therapeutic options for Acinetobacter baumannii infections. Expert Opinion on Pharmacotherapy 9:4, pages 587-599.
Read now
Read now
Varsha Gupta. (2008) Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species. Expert Opinion on Investigational Drugs 17:2, pages 131-143.
Read now
Read now
Articles from other publishers (71)
Anup R. Warrier & Sneha Radha. 2024. Acinetobacter baumannii - The Rise of a Resistant Pathogen. Acinetobacter baumannii - The Rise of a Resistant Pathogen.
John O'Donnell, Angela Tanudra, April Chen, Joseph Newman, Sarah M. McLeod & Rubén Tommasi. (2024)
In vivo
dose response and efficacy of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against the
Acinetobacter baumannii-calcoaceticus
complex
. Antimicrobial Agents and Chemotherapy 68:1.
Crossref
Crossref
Emilio Bouza, Patricia Muñoz & Almudena Burillo. (2023) How to treat severe Acinetobacter baumannii infections. Current Opinion in Infectious Diseases 36:6, pages 596-608.
Crossref
Crossref
Pranita D Tamma, Samuel L Aitken, Robert A Bonomo, Amy J Mathers, David van Duin & Cornelius J Clancy. (2023) Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clinical Infectious Diseases.
Crossref
Crossref
Marco Merli, Federico D’Amico, Giovanna Travi & Massimo Puoti. (2023) Current State of Antimicrobial Treatment of Lower Respiratory Tract Infections Due to Carbapenem-Resistant Acinetobacter baumannii. Future Pharmacology 3:2, pages 473-487.
Crossref
Crossref
John P O’Donnell & Sujata M Bhavnani. (2023)
The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus
Acinetobacter baumannii-calcoaceticus
Complex
. Clinical Infectious Diseases 76:Supplement_2, pages S202-S209.
Crossref
Crossref
Ryan K Shields, David L Paterson & Pranita D Tamma. (2023)
Navigating Available Treatment Options for Carbapenem-Resistant
Acinetobacter baumannii-calcoaceticus
Complex Infections
. Clinical Infectious Diseases 76:Supplement_2, pages S179-S193.
Crossref
Crossref
Gowthami Sai Kogilathota Jagirdhar, Kaanthi Rama, Shiva Teja Reddy, Harsha Pattnaik, Rakhtan K. Qasba, Praveen Reddy Elmati, Rahul Kashyap, Marco Schito & Nitin Gupta. (2023) Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature. Antibiotics 12:3, pages 582.
Crossref
Crossref
Tetsushu Onita, Kazuro Ikawa, Noriyuki Ishihara, Hiroki Tamaki, Takahisa Yano, Kohji Naora & Norifumi Morikawa. (2023) Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including Acinetobacter baumannii. Antibiotics 12:2, pages 303.
Crossref
Crossref
Mahtabalsadat Mirjalili, Farid Zand, Iman Karimzadeh, Mansoor Masjedi, Golnar Sabetian, Ehsan Mirzaei & Afsaneh Vazin. (2023) The clinical and paraclinical effectiveness of four-hour infusion vs. half-hour infusion of high-dose ampicillin-sulbactam in treatment of critically ill patients with sepsis or septic shock: An assessor-blinded randomized clinical trial. Journal of Critical Care 73, pages 154170.
Crossref
Crossref
Braden T. Tierney, Nitin K. Singh, Anna C. Simpson, Andrea M. Hujer, Robert A. Bonomo, Christopher E. Mason & Kasthuri Venkateswaran. (2022) Multidrug-resistant Acinetobacter pittii is adapting to and exhibiting potential succession aboard the International Space Station. Microbiome 10:1.
Crossref
Crossref
Sazlyna Mohd Sazlly Lim, Aaron Heffernan, Saiyuri Naicker, Steven Wallis, Jason A. Roberts & Fekade Bruck Sime. (2022) Evaluation of Fosfomycin-Sulbactam Combination Therapy against Carbapenem-Resistant Acinetobacter baumannii Isolates in a Hollow-Fibre Infection Model. Antibiotics 11:11, pages 1578.
Crossref
Crossref
Yanling Deng, Lin Chen, Mingrui Yue, Xiaobo Huang, Yang Yang & Hua Yu. (2022) Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia. BMC Infectious Diseases 22:1.
Crossref
Crossref
Chutchawan Ungthammakhun, Vasin Vasikasin & Dhitiwat Changpradub. (2022) A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis. Antibiotics 11:8, pages 1112.
Crossref
Crossref
Helen Giamarellou & Ilias Karaiskos. (2022) Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients. Antibiotics 11:8, pages 1009.
Crossref
Crossref
Pranita D Tamma, Samuel L Aitken, Robert A Bonomo, Amy J Mathers, David van Duin & Cornelius J Clancy. (2022)
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant
Acinetobacter baumannii
, and
Stenotrophomonas maltophilia
Infections
. Clinical Infectious Diseases 74:12, pages 2089-2114.
Crossref
Crossref
Erika Casarotta, Elisa Bottari, Sara Vannicola, Rachele Giorgetti, Roberta Domizi, Andrea Carsetti, Elisa Damiani, Claudia Scorcella, Vincenzo Gabbanelli, Simona Pantanetti, Benedetto Marini, Abele Donati & Erica Adrario. (2022) Antibiotic Treatment of Acinetobacter baumannii Superinfection in Patients With SARS-CoV-2 Infection Admitted to Intensive Care Unit: An Observational Retrospective Study. Frontiers in Medicine 9.
Crossref
Crossref
Cheng Len Sy, Pao-Yu Chen, Chun-Wen Cheng, Ling-Ju Huang, Ching-Hsun Wang, Tu-Hsuan Chang, Yi-Chin Chang, Chia-Jung Chang, Ing-Moi Hii, Yu-Lung Hsu, Ya-Li Hu, Pi-Lien Hung, Chen-Yen Kuo, Pei-Chin Lin, Po-Yen Liu, Ching-Lung Lo, Shih-Hao Lo, Pei-Ju Ting, Chien-Fang Tseng, Hsiao-Wei Wang, Ching-Hsiang Yang, Susan Shin-Jung Lee, Yao-Shen Chen, Yung-Ching Liu & Fu-Der Wang. (2022) Recommendations and guidelines for the treatment of infections due to multidrug resistant organisms. Journal of Microbiology, Immunology and Infection 55:3, pages 359-386.
Crossref
Crossref
Chien-Ming Chao, Chih-Cheng Lai, Chen-Hsiang Lee & Hung-Jen Tang. (2022) Optimal Dose of Cefoperazone-Sulbactam for Acute Bacterial Infection in Patients with Chronic Kidney Disease. Antibiotics 11:5, pages 610.
Crossref
Crossref
Carmi Bartal, Kenneth V. I. Rolston & Lior Nesher. (2022) Carbapenem-resistant Acinetobacter baumannii: Colonization, Infection and Current Treatment Options. Infectious Diseases and Therapy 11:2, pages 683-694.
Crossref
Crossref
Abdullah Tarık Aslan & Murat Akova. (2022) The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations. Antibiotics 11:2, pages 277.
Crossref
Crossref
Milo Gatti, Bruno Viaggi, Gian Maria Rossolini, Federico Pea & Pierluigi Viale. (2021) An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients. Antibiotics 11:1, pages 33.
Crossref
Crossref
Jacinda C. Abdul-Mutakabbir, Nicole C. Griffith, Ryan K. Shields, Frank P. Tverdek & Zahra Kassamali Escobar. (2021) Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists. Infectious Diseases and Therapy 10:4, pages 2177-2202.
Crossref
Crossref
J. Nicholas O'Donnell, Vibert Putra & Thomas P. Lodise. (2021)
Treatment of patients with serious infections due to carbapenem‐resistant
Acinetobacter baumannii
: How viable are the current options?
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41:9, pages 762-780.
Crossref
Crossref
Erin K. McCreary, Emily L. Heil & Pranita D. Tamma. (2021) New Perspectives on Antimicrobial Agents: Cefiderocol. Antimicrobial Agents and Chemotherapy 65:8.
Crossref
Crossref
Weerayuth Saelim, Dhitiwat Changpradub, Sudaluck Thunyaharn, Piraporn Juntanawiwat, Parnrada Nulsopapon & Wichai Santimaleeworagun. (2021)
Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant
Acinetobacter baumannii
: Improved Efficacy or Decreased Risk of Nephrotoxicity?
. Infection & Chemotherapy 53:1, pages 128.
Crossref
Crossref
Mohamed Ahmed Mahmoud Abdel Reheim, Ibrahim Saad Abdel Hafiz & Mohamed Ahmed Elian. (2020) Synthesis and Antimicrobial Evaluation of Some Novel Pyrimidine, Pyrazole, Chromene and Tetrahydrobenzo[b]thiophene Derivatives Bearing Pyrimidinthione Moiety. Current Organic Synthesis 17:7, pages 548-557.
Crossref
Crossref
Jameela Al Salman, Laila Al Dabal, Matteo Bassetti, Wadha A. Alfouzan, Muna Al Maslamani, Basem Alraddadi, Ashraf Elhoufi, Mushira Enani, Faryal Ali Khamis, Eiman Mokkadas, Ingy Romany, Ali Somily & Souha Kanj. (2020) Management of infections caused by WHO critical priority Gram-negative pathogens in Arab countries of the Middle East: a consensus paper. International Journal of Antimicrobial Agents 56:4, pages 106104.
Crossref
Crossref
Sarah Melissa Nørgaard, Camilla Skaarup Jensen, Josefine Aalestrup, Christina M. J. E. Vandenbroucke-Grauls, Mark G. J. de Boer & Alma Becic Pedersen. (2019) Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review. Antimicrobial Resistance & Infection Control 8:1.
Crossref
Crossref
Julio César García, Henry Robayo Amortegui & Adriana Carrasco Márquez. (2019) Multirresistencia de Acinetobacter baumannii: revisión narrativa. Acta Colombiana de Cuidado Intensivo 19:4, pages 219-226.
Crossref
Crossref
Burcu Isler, Yohei Doi, Robert A. Bonomo & David L. Paterson. (2019)
New Treatment Options against Carbapenem-Resistant
Acinetobacter baumannii
Infections
. Antimicrobial Agents and Chemotherapy 63:1.
Crossref
Crossref
Phillip J. Bergen, Nicholas M. Smith, Tyler B. Bedard, Zackery P. Bulman, Raymond Cha & Brian T. Tsuji. 2019. Polymyxin Antibiotics: From Laboratory Bench to Bedside. Polymyxin Antibiotics: From Laboratory Bench to Bedside
251
288
.
Jerry Altshuler, Samuel L. Aitken, Melanie Maslow, John Papadopoulos & Amar Safdar. 2019. Principles and Practice of Transplant Infectious Diseases. Principles and Practice of Transplant Infectious Diseases
855
901
.
Hossein Khalili, Lida Shojaei, Mostafa Mohammadi, Mohammad-Taghi Beigmohammadi, Alireza Abdollahi & Mahsa Doomanlou. (2018) Meropenem/colistin versus meropenem/ampicillin–sulbactam in the treatment of carbapenem-resistant pneumonia. Journal of Comparative Effectiveness Research 7:9, pages 901-911.
Crossref
Crossref
Peter M Hawkey, Roderic E Warren, David M Livermore, Cliodna A M McNulty, David A Enoch, Jonathan A Otter & A Peter R Wilson. (2018) Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†. Journal of Antimicrobial Chemotherapy 73:suppl_3, pages iii2-iii78.
Crossref
Crossref
Sombat Leelasupasri, Wichai Santimaleeworagun & Tossawan Jitwasinkul. (2018)
Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant
Acinetobacter baumannii
. Journal of Pathogens 2018, pages 1-5.
Crossref
Crossref
Kirati Kengkla, Khachen Kongpakwattana, Surasak Saokaew, Anucha Apisarnthanarak & Nathorn Chaiyakunapruk. (2018) Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. Journal of Antimicrobial Chemotherapy 73:1, pages 22-32.
Crossref
Crossref
Su Young Jung, Seung Hee Lee, Soo Young Lee, Seungwon Yang, Hayeon Noh, Eun Kyoung Chung & Jangik I. Lee. (2017) Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Critical Care 21:1.
Crossref
Crossref
Eric Wenzler, Debra A. Goff, Romney Humphries & Ellie J. C. Goldstein. (2017) Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections. Infectious Diseases and Therapy 6:2, pages 149-172.
Crossref
Crossref
Justin R. Lenhard, Visanu Thamlikitkul, Fernanda P. Silveira, Samira M. Garonzik, Xun Tao, Alan Forrest, Beom Soo Shin, Keith S. Kaye, Jürgen B. Bulitta, Roger L. Nation, Jian Li & Brian T. Tsuji. (2017) Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity. Journal of Antimicrobial Chemotherapy 72:5, pages 1415-1420.
Crossref
Crossref
Justin R. Lenhard, Nicholas M. Smith, Zackery P. Bulman, Xun Tao, Visanu Thamlikitkul, Beom S. Shin, Roger L. Nation, Jian Li, Jürgen B. Bulitta & Brian T. Tsuji. (2017) High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy 61:3.
Crossref
Crossref
Jung-Jr Ye, Huang-Shen Lin, Chun-Fu Yeh, Yen-Mu Wu, Po-Yen Huang, Chien-Chang Yang, Ching-Tai Huang & Ming-Hsun Lee. (2016) Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. BMC Infectious Diseases 16:1.
Crossref
Crossref
Sutep Jaruratanasirikul, Wibul Wongpoowarak, Thitima Wattanavijitkul, Waroonrat Sukarnjanaset, Maseetoh Samaeng, Monchana Nawakitrangsan & Natnicha Ingviya. (2016) Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy 60:12, pages 7236-7244.
Crossref
Crossref
In Beom Jeong, Moon Jun Na, Ji Woong Son, Do Yeon Jo & Sun Jung Kwon. (2016) High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter Baumannii. The Korean Journal of Critical Care Medicine 31:4, pages 308-316.
Crossref
Crossref
Andre C. Kalil, Mark L. Metersky, Michael Klompas, John Muscedere, Daniel A. Sweeney, Lucy B. Palmer, Lena M. Napolitano, Naomi P. O'Grady, John G. Bartlett, Jordi Carratalà, Ali A. El Solh, Santiago Ewig, Paul D. Fey, Thomas M. FileJrJr, Marcos I. Restrepo, Jason A. Roberts, Grant W. Waterer, Peggy Cruse, Shandra L. Knight & Jan L. Brozek. (2016) Management of Adults With Hospital-acquired and Ventilator-associated
Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America
and the American Thoracic Society. Clinical Infectious Diseases 63:5, pages e61-e111.
Crossref
Crossref
Santiago Ewig & Sören Gaterm. 2016. Pneumonie. Pneumonie
1
17
.
José Garnacho-Montero, George Dimopoulos, Garyphallia Poulakou, Murat Akova, José Miguel Cisneros, Jan De Waele, Nicola Petrosillo, Harald Seifert, Jean François Timsit, Jordi Vila, Jean-Ralph Zahar & Matteo Bassetti. (2015) Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Medicine 41:12, pages 2057-2075.
Crossref
Crossref
Debra A. Goff, Karri A. Bauer & Julie E. Mangino. (2014) Bad Bugs Need Old Drugs: A Stewardship Program's Evaluation of Minocycline for Multidrug-Resistant Acinetobacter baumannii Infections. Clinical Infectious Diseases 59:suppl_6, pages S381-S387.
Crossref
Crossref
Rocío Álvarez-Marín, José Molina Gil-Bermejo & José M. Cisneros. (2014) Epidemiology and Treatment of Multidrug-Resistant Acinetobacter baumannii. Current Treatment Options in Infectious Diseases 6:4, pages 409-424.
Crossref
Crossref
J.T. Kielstein. (2014) Die adäquate Dosierung von AntiinfektivaDosing of antibiotics during extracorporeal therapies. Wiener klinisches Magazin 17:5, pages 36-41.
Crossref
Crossref
P. Poulikakos, G. S. Tansarli & M. E. Falagas. (2014) Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. European Journal of Clinical Microbiology & Infectious Diseases 33:10, pages 1675-1685.
Crossref
Crossref
J.T. Kielstein. (2014) Medikamentendosierung unter extrakorporaler TherapieDrug dosing in extracorporeal therapy. Medizinische Klinik - Intensivmedizin und Notfallmedizin 109:5, pages 348-353.
Crossref
Crossref
Syamhanin Adnan, David L. Paterson, Jeffrey Lipman & Jason A. Roberts. (2013) Ampicillin/sulbactam: Its potential use in treating infections in critically ill patients. International Journal of Antimicrobial Agents 42:5, pages 384-389.
Crossref
Crossref
A. Baranzelli, F. Wallyn & S. Nseir. (2013) Infections bronchopulmonaires à Stenotrophomonas maltophilia et à Acinetobacter baumannii. Revue de Pneumologie Clinique 69:5, pages 250-259.
Crossref
Crossref
Sutep Jaruratanasirikul, Wibul Wongpoowarak, Nanchanit Aeinlang & Monchana Jullangkoon. (2013) Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam. Antimicrobial Agents and Chemotherapy 57:7, pages 3441-3444.
Crossref
Crossref
M. Eveillard & M.-L. Joly-Guillou. (2012) Infections émergentes à Acinetobacter baumannii et circonstances favorisant leur survenue. Pathologie Biologie 60:5, pages 314-319.
Crossref
Crossref
Alberto Sandiumenge & Jordi Rello. (2012) Ventilator-associated pneumonia caused by ESKAPE organisms. Current Opinion in Pulmonary Medicine 18:3, pages 187-193.
Crossref
Crossref
Johan M. Lorenzen, Michael Broll, Volkhard Kaever, Heike Burhenne, Carsten Hafer, Christian Clajus, Wolfgang Knitsch, Olaf Burkhardt & Jan T. Kielstein. (2012) Pharmacokinetics of Ampicillin/Sulbactam in Critically Ill Patients with Acute Kidney Injury undergoing Extended Dialysis. Clinical Journal of the American Society of Nephrology 7:3, pages 385-390.
Crossref
Crossref
Jeannie D. ChanJoseph A. Graves & Timothy H. Dellit. (2010) Antimicrobial Treatment and Clinical Outcomes of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia. Journal of Intensive Care Medicine 25:6, pages 343-348.
Crossref
Crossref
Michael PfallerPetros Rafailidis & Matthew Falagas. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
204
220
.
Michael PfallerPaschalis Vergidis & Matthew Falagas. 2010. Kucers' The Use of Antibiotics Sixth Edition. Kucers' The Use of Antibiotics Sixth Edition
175
179
.
José Garnacho-Montero & Rosario Amaya-Villar. (2010) Multiresistant Acinetobacter baumannii infections: epidemiology and management. Current Opinion in Infectious Diseases 23:4, pages 332-339.
Crossref
Crossref
Drosos E Karageorgopoulos & Matthew E Falagas. (2008) Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. The Lancet Infectious Diseases 8:12, pages 751-762.
Crossref
Crossref
. (2008) 21st ESICM Annual Congress. Intensive Care Medicine 34:S1, pages 181-268.
Crossref
Crossref
Helen Giamarellou, Anastasia Antoniadou & Kyriaki Kanellakopoulou. (2008) Acinetobacter baumannii: a universal threat to public health?. International Journal of Antimicrobial Agents 32:2, pages 106-119.
Crossref
Crossref
Anton Y. Peleg, Harald Seifert & David L. Paterson. (2008)
Acinetobacter baumannii
: Emergence of a Successful Pathogen
. Clinical Microbiology Reviews 21:3, pages 538-582.
Crossref
Crossref
Hartmut M. Lode. (2008) Rational antibiotic therapy and the position of ampicillin/sulbactam. International Journal of Antimicrobial Agents 32:1, pages 10-28.
Crossref
Crossref
Alex P. Betrosian, Frantzeska Frantzeskaki, Anna Xanthaki & Emmanuel E. Douzinas. (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Journal of Infection 56:6, pages 432-436.
Crossref
Crossref
Clinton K. Murray & Duane R. Hospenthal. (2008) Acinetobacter Infection in the ICU. Critical Care Clinics 24:2, pages 237-248.
Crossref
Crossref
L. Silvia Munoz-Price & Robert A. Weinstein. (2008) Acinetobacter Infection. New England Journal of Medicine 358:12, pages 1271-1281.
Crossref
Crossref
Anthony M. Nicasio, Joseph L. Kuti & David P. Nicolau. (2012) The Current State of Multidrug‐Resistant Gram‐Negative Bacilli in North America. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 28:2, pages 235-249.
Crossref
Crossref